nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—IRAK4—prostate cancer	0.0896	0.208	CbGaD
Sunitinib—MAP3K7—prostate cancer	0.0679	0.158	CbGaD
Sunitinib—MAP2K1—prostate cancer	0.0577	0.134	CbGaD
Sunitinib—CHEK2—prostate cancer	0.0462	0.107	CbGaD
Sunitinib—JAK2—prostate cancer	0.0438	0.102	CbGaD
Sunitinib—FGFR2—prostate cancer	0.043	0.1	CbGaD
Sunitinib—PDGFRB—prostate cancer	0.034	0.0791	CbGaD
Sunitinib—KDR—prostate cancer	0.0258	0.0599	CbGaD
Sunitinib—CYP3A5—prostate cancer	0.0156	0.0362	CbGaD
Sunitinib—ABCC4—Conjugated Estrogens—prostate cancer	0.0127	0.0644	CbGbCtD
Sunitinib—ABCG2—Cabazitaxel—prostate cancer	0.0107	0.0541	CbGbCtD
Sunitinib—ABCG2—Estrone—prostate cancer	0.0104	0.0529	CbGbCtD
Sunitinib—ABCC2—Ethinyl Estradiol—prostate cancer	0.0103	0.0522	CbGbCtD
Sunitinib—CYP3A5—Flutamide—prostate cancer	0.008	0.0405	CbGbCtD
Sunitinib—ABCC2—Conjugated Estrogens—prostate cancer	0.00755	0.0383	CbGbCtD
Sunitinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00716	0.0363	CbGbCtD
Sunitinib—ABCG2—Conjugated Estrogens—prostate cancer	0.00683	0.0346	CbGbCtD
Sunitinib—CYP3A4—prostate cancer	0.00674	0.0157	CbGaD
Sunitinib—ABCG2—Mitoxantrone—prostate cancer	0.0062	0.0315	CbGbCtD
Sunitinib—ABCG2—Estradiol—prostate cancer	0.00599	0.0304	CbGbCtD
Sunitinib—CYP3A5—Cabazitaxel—prostate cancer	0.00591	0.03	CbGbCtD
Sunitinib—ABCB1—Estramustine—prostate cancer	0.00584	0.0296	CbGbCtD
Sunitinib—CYP3A5—Estrone—prostate cancer	0.00578	0.0293	CbGbCtD
Sunitinib—CYP3A7—Estradiol—prostate cancer	0.00443	0.0224	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.00443	0.0224	CbGbCtD
Sunitinib—ABCC2—Etoposide—prostate cancer	0.00433	0.0219	CbGbCtD
Sunitinib—ABCC2—Docetaxel—prostate cancer	0.00396	0.0201	CbGbCtD
Sunitinib—ABCG2—Etoposide—prostate cancer	0.00391	0.0198	CbGbCtD
Sunitinib—ABCB1—Cabazitaxel—prostate cancer	0.00385	0.0195	CbGbCtD
Sunitinib—CYP3A4—Bicalutamide—prostate cancer	0.00376	0.0191	CbGbCtD
Sunitinib—ABCB1—Estrone—prostate cancer	0.00376	0.0191	CbGbCtD
Sunitinib—ABCG2—Docetaxel—prostate cancer	0.00358	0.0182	CbGbCtD
Sunitinib—CYP3A4—Estramustine—prostate cancer	0.0035	0.0177	CbGbCtD
Sunitinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00335	0.017	CbGbCtD
Sunitinib—CYP3A5—Estradiol—prostate cancer	0.00332	0.0168	CbGbCtD
Sunitinib—CYP3A4—Flutamide—prostate cancer	0.00312	0.0158	CbGbCtD
Sunitinib—CYP3A4—Abiraterone—prostate cancer	0.00312	0.0158	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—prostate cancer	0.00295	0.015	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—prostate cancer	0.00267	0.0135	CbGbCtD
Sunitinib—CYP3A7—Docetaxel—prostate cancer	0.00264	0.0134	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00264	0.0134	CbGbCtD
Sunitinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00246	0.0125	CbGbCtD
Sunitinib—CYP3A4—Cabazitaxel—prostate cancer	0.00231	0.0117	CbGbCtD
Sunitinib—CYP3A4—Estrone—prostate cancer	0.00225	0.0114	CbGbCtD
Sunitinib—ABCB1—Mitoxantrone—prostate cancer	0.00224	0.0113	CbGbCtD
Sunitinib—CYP3A5—Etoposide—prostate cancer	0.00217	0.011	CbGbCtD
Sunitinib—ABCB1—Estradiol—prostate cancer	0.00216	0.011	CbGbCtD
Sunitinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00201	0.0102	CbGbCtD
Sunitinib—CYP3A5—Docetaxel—prostate cancer	0.00198	0.0101	CbGbCtD
Sunitinib—ABCB1—Prednisone—prostate cancer	0.00186	0.00942	CbGbCtD
Sunitinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00147	0.00748	CbGbCtD
Sunitinib—ABCB1—Etoposide—prostate cancer	0.00141	0.00715	CbGbCtD
Sunitinib—CYP3A4—Mitoxantrone—prostate cancer	0.00134	0.0068	CbGbCtD
Sunitinib—CYP3A4—Estradiol—prostate cancer	0.00129	0.00656	CbGbCtD
Sunitinib—ABCB1—Docetaxel—prostate cancer	0.00129	0.00655	CbGbCtD
Sunitinib—CYP3A4—Prednisone—prostate cancer	0.00111	0.00565	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—prostate cancer	0.000962	0.00488	CbGbCtD
Sunitinib—CYP3A4—Etoposide—prostate cancer	0.000845	0.00429	CbGbCtD
Sunitinib—CYP3A4—Docetaxel—prostate cancer	0.000773	0.00392	CbGbCtD
Sunitinib—CYP3A4—Doxorubicin—prostate cancer	0.000577	0.00292	CbGbCtD
Sunitinib—Metoclopramide—CYP17A1—prostate cancer	0.000572	0.284	CrCbGaD
Sunitinib—Procainamide—DNMT1—prostate cancer	0.00053	0.264	CrCbGaD
Sunitinib—Procainamide—SLC22A3—prostate cancer	0.000347	0.172	CrCbGaD
Sunitinib—Procainamide—ACHE—prostate cancer	0.000314	0.156	CrCbGaD
Sunitinib—Procainamide—SLC22A1—prostate cancer	0.000249	0.124	CrCbGaD
Sunitinib—CHEK2—Docetaxel—Cabazitaxel—prostate cancer	0.000241	0.0938	CbGdCrCtD
Sunitinib—MAP4K4—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	0.000189	0.0735	CbGdCrCtD
Sunitinib—CHEK2—Paclitaxel—Cabazitaxel—prostate cancer	0.000167	0.0647	CbGdCrCtD
Sunitinib—STK24—Teniposide—Etoposide—prostate cancer	0.000158	0.0615	CbGdCrCtD
Sunitinib—TLK2—Levorphanol—Estrone—prostate cancer	0.000133	0.0518	CbGdCrCtD
Sunitinib—FGFR2—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000125	0.0485	CbGdCrCtD
Sunitinib—FLT1—epithelium—prostate cancer	0.000121	0.00132	CbGeAlD
Sunitinib—HIPK2—testis—prostate cancer	0.00012	0.00132	CbGeAlD
Sunitinib—HIPK3—testis—prostate cancer	0.00012	0.00132	CbGeAlD
Sunitinib—TYRO3—testis—prostate cancer	0.00012	0.00132	CbGeAlD
Sunitinib—ALK—testis—prostate cancer	0.00012	0.00132	CbGeAlD
Sunitinib—ITK—lymph node—prostate cancer	0.00012	0.00132	CbGeAlD
Sunitinib—SBK1—lymph node—prostate cancer	0.00012	0.00132	CbGeAlD
Sunitinib—PDGFRB—prostate gland—prostate cancer	0.00012	0.00131	CbGeAlD
Sunitinib—JAK2—renal system—prostate cancer	0.00012	0.00131	CbGeAlD
Sunitinib—FLT3—bone marrow—prostate cancer	0.00012	0.00131	CbGeAlD
Sunitinib—SLK—urethra—prostate cancer	0.00012	0.00131	CbGeAlD
Sunitinib—RIOK2—testis—prostate cancer	0.000119	0.0013	CbGeAlD
Sunitinib—TNK1—testis—prostate cancer	0.000119	0.0013	CbGeAlD
Sunitinib—BLK—lymph node—prostate cancer	0.000119	0.0013	CbGeAlD
Sunitinib—FYN—renal system—prostate cancer	0.000118	0.00129	CbGeAlD
Sunitinib—RPS6KA3—bone marrow—prostate cancer	0.000118	0.00129	CbGeAlD
Sunitinib—MAP3K19—testis—prostate cancer	0.000118	0.00129	CbGeAlD
Sunitinib—MAP4K1—testis—prostate cancer	0.000118	0.00129	CbGeAlD
Sunitinib—JAK2—urethra—prostate cancer	0.000118	0.00129	CbGeAlD
Sunitinib—PHKG1—lymph node—prostate cancer	0.000118	0.00129	CbGeAlD
Sunitinib—DAPK1—lymph node—prostate cancer	0.000118	0.00129	CbGeAlD
Sunitinib—KDR—seminal vesicle—prostate cancer	0.000117	0.00128	CbGeAlD
Sunitinib—MAP2K5—seminal vesicle—prostate cancer	0.000117	0.00128	CbGeAlD
Sunitinib—MAP2K1—bone marrow—prostate cancer	0.000117	0.00128	CbGeAlD
Sunitinib—FYN—urethra—prostate cancer	0.000116	0.00127	CbGeAlD
Sunitinib—CSNK1A1—bone marrow—prostate cancer	0.000116	0.00127	CbGeAlD
Sunitinib—DAPK3—testis—prostate cancer	0.000116	0.00126	CbGeAlD
Sunitinib—CLK1—bone marrow—prostate cancer	0.000115	0.00126	CbGeAlD
Sunitinib—CLK2—testis—prostate cancer	0.000115	0.00125	CbGeAlD
Sunitinib—CSF1R—seminal vesicle—prostate cancer	0.000115	0.00125	CbGeAlD
Sunitinib—MAP4K2—testis—prostate cancer	0.000114	0.00125	CbGeAlD
Sunitinib—BRD4—lymph node—prostate cancer	0.000114	0.00125	CbGeAlD
Sunitinib—STK11—lymph node—prostate cancer	0.000114	0.00125	CbGeAlD
Sunitinib—MAP4K5—urethra—prostate cancer	0.000114	0.00124	CbGeAlD
Sunitinib—MAP3K3—urethra—prostate cancer	0.000114	0.00124	CbGeAlD
Sunitinib—CAMK2G—bone marrow—prostate cancer	0.000113	0.00123	CbGeAlD
Sunitinib—BMP2K—bone marrow—prostate cancer	0.000113	0.00123	CbGeAlD
Sunitinib—RPS6KA1—lymph node—prostate cancer	0.000113	0.00123	CbGeAlD
Sunitinib—RIOK1—lymph node—prostate cancer	0.000113	0.00123	CbGeAlD
Sunitinib—STK3—testis—prostate cancer	0.000113	0.00123	CbGeAlD
Sunitinib—LRRK2—bone marrow—prostate cancer	0.000112	0.00122	CbGeAlD
Sunitinib—FLT1—renal system—prostate cancer	0.000112	0.00122	CbGeAlD
Sunitinib—ROCK1—testis—prostate cancer	0.000111	0.00121	CbGeAlD
Sunitinib—MARK2—lymph node—prostate cancer	0.000111	0.00121	CbGeAlD
Sunitinib—TNIK—lymph node—prostate cancer	0.000111	0.00121	CbGeAlD
Sunitinib—PRKAA1—bone marrow—prostate cancer	0.00011	0.00121	CbGeAlD
Sunitinib—FLT1—urethra—prostate cancer	0.00011	0.0012	CbGeAlD
Sunitinib—SGK3—lymph node—prostate cancer	0.00011	0.0012	CbGeAlD
Sunitinib—PTK2B—bone marrow—prostate cancer	0.000109	0.00119	CbGeAlD
Sunitinib—FLT4—bone marrow—prostate cancer	0.000109	0.00119	CbGeAlD
Sunitinib—EPHB6—urethra—prostate cancer	0.000109	0.00119	CbGeAlD
Sunitinib—ICK—lymph node—prostate cancer	0.000109	0.00119	CbGeAlD
Sunitinib—DYRK1A—testis—prostate cancer	0.000108	0.00118	CbGeAlD
Sunitinib—YES1—renal system—prostate cancer	0.000107	0.00117	CbGeAlD
Sunitinib—FGFR2—Estradiol—Estramustine—prostate cancer	0.000106	0.0413	CbGdCrCtD
Sunitinib—STK10—renal system—prostate cancer	0.000106	0.00116	CbGeAlD
Sunitinib—MERTK—testis—prostate cancer	0.000106	0.00116	CbGeAlD
Sunitinib—IRAK4—bone marrow—prostate cancer	0.000106	0.00115	CbGeAlD
Sunitinib—TAOK3—renal system—prostate cancer	0.000106	0.00115	CbGeAlD
Sunitinib—YES1—urethra—prostate cancer	0.000105	0.00115	CbGeAlD
Sunitinib—CHEK2—lymph node—prostate cancer	0.000105	0.00115	CbGeAlD
Sunitinib—NUAK1—lymph node—prostate cancer	0.000105	0.00115	CbGeAlD
Sunitinib—PDGFRA—renal system—prostate cancer	0.000105	0.00115	CbGeAlD
Sunitinib—SNRK—lymph node—prostate cancer	0.000104	0.00114	CbGeAlD
Sunitinib—INSR—lymph node—prostate cancer	0.000104	0.00114	CbGeAlD
Sunitinib—OXSR1—lymph node—prostate cancer	0.000104	0.00114	CbGeAlD
Sunitinib—KIT—seminal vesicle—prostate cancer	0.000104	0.00114	CbGeAlD
Sunitinib—MAP4K4—testis—prostate cancer	0.000104	0.00114	CbGeAlD
Sunitinib—TAOK3—urethra—prostate cancer	0.000104	0.00113	CbGeAlD
Sunitinib—ULK3—bone marrow—prostate cancer	0.000103	0.00113	CbGeAlD
Sunitinib—MAP2K2—bone marrow—prostate cancer	0.000103	0.00113	CbGeAlD
Sunitinib—NUAK2—testis—prostate cancer	0.000103	0.00113	CbGeAlD
Sunitinib—MAP3K2—bone marrow—prostate cancer	0.000103	0.00112	CbGeAlD
Sunitinib—MAP3K12—testis—prostate cancer	0.000102	0.00112	CbGeAlD
Sunitinib—FLT3—testis—prostate cancer	0.000102	0.00112	CbGeAlD
Sunitinib—RPS6KA2—lymph node—prostate cancer	0.000102	0.00112	CbGeAlD
Sunitinib—STK38—lymph node—prostate cancer	0.000102	0.00112	CbGeAlD
Sunitinib—KDR—epithelium—prostate cancer	0.000102	0.00111	CbGeAlD
Sunitinib—MAP3K7—bone marrow—prostate cancer	0.000102	0.00111	CbGeAlD
Sunitinib—AURKC—lymph node—prostate cancer	0.000102	0.00111	CbGeAlD
Sunitinib—PDGFRB—seminal vesicle—prostate cancer	0.000102	0.00111	CbGeAlD
Sunitinib—TLK2—Levorphanol—Estradiol—prostate cancer	0.000101	0.0393	CbGdCrCtD
Sunitinib—RPS6KA3—testis—prostate cancer	0.000101	0.0011	CbGeAlD
Sunitinib—CSNK1G2—lymph node—prostate cancer	0.000101	0.0011	CbGeAlD
Sunitinib—PKN1—lymph node—prostate cancer	0.000101	0.0011	CbGeAlD
Sunitinib—TBK1—bone marrow—prostate cancer	0.0001	0.0011	CbGeAlD
Sunitinib—MAP2K1—testis—prostate cancer	0.0001	0.0011	CbGeAlD
Sunitinib—TYK2—bone marrow—prostate cancer	9.98e-05	0.00109	CbGeAlD
Sunitinib—PRPF4—lymph node—prostate cancer	9.94e-05	0.00109	CbGeAlD
Sunitinib—CSNK1A1—testis—prostate cancer	9.9e-05	0.00108	CbGeAlD
Sunitinib—IRAK1—bone marrow—prostate cancer	9.85e-05	0.00108	CbGeAlD
Sunitinib—CLK1—testis—prostate cancer	9.84e-05	0.00108	CbGeAlD
Sunitinib—PRPF4B—lymph node—prostate cancer	9.8e-05	0.00107	CbGeAlD
Sunitinib—RPS6KB1—bone marrow—prostate cancer	9.67e-05	0.00106	CbGeAlD
Sunitinib—STK39—lymph node—prostate cancer	9.66e-05	0.00106	CbGeAlD
Sunitinib—CAMK2G—testis—prostate cancer	9.66e-05	0.00106	CbGeAlD
Sunitinib—BMP2K—testis—prostate cancer	9.66e-05	0.00106	CbGeAlD
Sunitinib—FGR—bone marrow—prostate cancer	9.61e-05	0.00105	CbGeAlD
Sunitinib—LRRK2—testis—prostate cancer	9.57e-05	0.00105	CbGeAlD
Sunitinib—ABCC4—prostate gland—prostate cancer	9.57e-05	0.00105	CbGeAlD
Sunitinib—CSNK2A1—lymph node—prostate cancer	9.53e-05	0.00104	CbGeAlD
Sunitinib—KDR—renal system—prostate cancer	9.46e-05	0.00103	CbGeAlD
Sunitinib—PRKAA1—testis—prostate cancer	9.43e-05	0.00103	CbGeAlD
Sunitinib—MYLK—lymph node—prostate cancer	9.41e-05	0.00103	CbGeAlD
Sunitinib—PTK2B—testis—prostate cancer	9.33e-05	0.00102	CbGeAlD
Sunitinib—FLT4—testis—prostate cancer	9.3e-05	0.00102	CbGeAlD
Sunitinib—PLK4—lymph node—prostate cancer	9.3e-05	0.00102	CbGeAlD
Sunitinib—MAP2K5—urethra—prostate cancer	9.29e-05	0.00102	CbGeAlD
Sunitinib—KDR—urethra—prostate cancer	9.29e-05	0.00102	CbGeAlD
Sunitinib—ABCC2—prostate gland—prostate cancer	9.26e-05	0.00101	CbGeAlD
Sunitinib—STK4—lymph node—prostate cancer	9.24e-05	0.00101	CbGeAlD
Sunitinib—SLK—bone marrow—prostate cancer	9.21e-05	0.00101	CbGeAlD
Sunitinib—CSNK1E—testis—prostate cancer	9.18e-05	0.001	CbGeAlD
Sunitinib—FGFR1—testis—prostate cancer	9.18e-05	0.001	CbGeAlD
Sunitinib—JAK2—bone marrow—prostate cancer	9.08e-05	0.000992	CbGeAlD
Sunitinib—PHKG2—lymph node—prostate cancer	9.08e-05	0.000992	CbGeAlD
Sunitinib—CSF1R—urethra—prostate cancer	9.07e-05	0.000991	CbGeAlD
Sunitinib—KIT—epithelium—prostate cancer	9.04e-05	0.000988	CbGeAlD
Sunitinib—IRAK4—testis—prostate cancer	9.04e-05	0.000987	CbGeAlD
Sunitinib—STK24—lymph node—prostate cancer	9.02e-05	0.000986	CbGeAlD
Sunitinib—FYN—bone marrow—prostate cancer	8.96e-05	0.000979	CbGeAlD
Sunitinib—DAPK2—lymph node—prostate cancer	8.92e-05	0.000975	CbGeAlD
Sunitinib—ULK3—testis—prostate cancer	8.83e-05	0.000965	CbGeAlD
Sunitinib—MAP2K2—testis—prostate cancer	8.83e-05	0.000965	CbGeAlD
Sunitinib—PDGFRB—epithelium—prostate cancer	8.83e-05	0.000965	CbGeAlD
Sunitinib—STK16—lymph node—prostate cancer	8.78e-05	0.000959	CbGeAlD
Sunitinib—MAP3K2—testis—prostate cancer	8.77e-05	0.000958	CbGeAlD
Sunitinib—MAP4K5—bone marrow—prostate cancer	8.75e-05	0.000956	CbGeAlD
Sunitinib—MAP3K3—bone marrow—prostate cancer	8.75e-05	0.000956	CbGeAlD
Sunitinib—HIPK3—lymph node—prostate cancer	8.73e-05	0.000954	CbGeAlD
Sunitinib—HIPK2—lymph node—prostate cancer	8.73e-05	0.000954	CbGeAlD
Sunitinib—ALK—lymph node—prostate cancer	8.73e-05	0.000954	CbGeAlD
Sunitinib—MAP3K7—testis—prostate cancer	8.69e-05	0.000949	CbGeAlD
Sunitinib—TNK1—lymph node—prostate cancer	8.64e-05	0.000944	CbGeAlD
Sunitinib—RIOK2—lymph node—prostate cancer	8.64e-05	0.000944	CbGeAlD
Sunitinib—TBK1—testis—prostate cancer	8.59e-05	0.000938	CbGeAlD
Sunitinib—MAP4K1—lymph node—prostate cancer	8.55e-05	0.000935	CbGeAlD
Sunitinib—TYK2—testis—prostate cancer	8.53e-05	0.000932	CbGeAlD
Sunitinib—FGFR2—Estradiol—Estrone—prostate cancer	8.44e-05	0.0328	CbGdCrCtD
Sunitinib—IRAK1—testis—prostate cancer	8.42e-05	0.00092	CbGeAlD
Sunitinib—DAPK3—lymph node—prostate cancer	8.39e-05	0.000917	CbGeAlD
Sunitinib—KIT—renal system—prostate cancer	8.38e-05	0.000916	CbGeAlD
Sunitinib—CLK2—lymph node—prostate cancer	8.31e-05	0.000908	CbGeAlD
Sunitinib—MAP4K2—lymph node—prostate cancer	8.27e-05	0.000904	CbGeAlD
Sunitinib—RPS6KB1—testis—prostate cancer	8.26e-05	0.000903	CbGeAlD
Sunitinib—KIT—urethra—prostate cancer	8.24e-05	0.0009	CbGeAlD
Sunitinib—RET—testis—prostate cancer	8.21e-05	0.000897	CbGeAlD
Sunitinib—FGR—testis—prostate cancer	8.21e-05	0.000897	CbGeAlD
Sunitinib—PDGFRB—renal system—prostate cancer	8.19e-05	0.000895	CbGeAlD
Sunitinib—AXL—testis—prostate cancer	8.18e-05	0.000894	CbGeAlD
Sunitinib—STK3—lymph node—prostate cancer	8.16e-05	0.000892	CbGeAlD
Sunitinib—YES1—bone marrow—prostate cancer	8.08e-05	0.000883	CbGeAlD
Sunitinib—PDGFRB—urethra—prostate cancer	8.04e-05	0.000879	CbGeAlD
Sunitinib—STK10—bone marrow—prostate cancer	8.01e-05	0.000875	CbGeAlD
Sunitinib—TAOK3—bone marrow—prostate cancer	7.98e-05	0.000872	CbGeAlD
Sunitinib—SLK—testis—prostate cancer	7.87e-05	0.00086	CbGeAlD
Sunitinib—DYRK1A—lymph node—prostate cancer	7.86e-05	0.000858	CbGeAlD
Sunitinib—FGFR2—testis—prostate cancer	7.8e-05	0.000853	CbGeAlD
Sunitinib—JAK2—testis—prostate cancer	7.76e-05	0.000848	CbGeAlD
Sunitinib—MERTK—lymph node—prostate cancer	7.67e-05	0.000838	CbGeAlD
Sunitinib—FYN—testis—prostate cancer	7.66e-05	0.000836	CbGeAlD
Sunitinib—KCNH2—prostate gland—prostate cancer	7.59e-05	0.000829	CbGeAlD
Sunitinib—MAP4K4—lymph node—prostate cancer	7.53e-05	0.000823	CbGeAlD
Sunitinib—MAP3K3—testis—prostate cancer	7.48e-05	0.000817	CbGeAlD
Sunitinib—MAP4K5—testis—prostate cancer	7.48e-05	0.000817	CbGeAlD
Sunitinib—NUAK2—lymph node—prostate cancer	7.48e-05	0.000817	CbGeAlD
Sunitinib—FGFR2—Estradiol—Conjugated Estrogens—prostate cancer	7.43e-05	0.0289	CbGdCrCtD
Sunitinib—MAP3K12—lymph node—prostate cancer	7.42e-05	0.000811	CbGeAlD
Sunitinib—FLT3—lymph node—prostate cancer	7.42e-05	0.000811	CbGeAlD
Sunitinib—RPS6KA3—lymph node—prostate cancer	7.32e-05	0.0008	CbGeAlD
Sunitinib—MAP2K1—lymph node—prostate cancer	7.27e-05	0.000795	CbGeAlD
Sunitinib—PRPF4—Fulvestrant—Estradiol—prostate cancer	7.24e-05	0.0281	CbGdCrCtD
Sunitinib—FLT1—testis—prostate cancer	7.23e-05	0.00079	CbGeAlD
Sunitinib—CSNK1A1—lymph node—prostate cancer	7.18e-05	0.000784	CbGeAlD
Sunitinib—KDR—bone marrow—prostate cancer	7.15e-05	0.000782	CbGeAlD
Sunitinib—EPHB6—testis—prostate cancer	7.15e-05	0.000781	CbGeAlD
Sunitinib—CLK1—lymph node—prostate cancer	7.13e-05	0.000779	CbGeAlD
Sunitinib—BMP2K—lymph node—prostate cancer	7e-05	0.000765	CbGeAlD
Sunitinib—CAMK2G—lymph node—prostate cancer	7e-05	0.000765	CbGeAlD
Sunitinib—CSF1R—bone marrow—prostate cancer	6.98e-05	0.000763	CbGeAlD
Sunitinib—LRRK2—lymph node—prostate cancer	6.94e-05	0.000758	CbGeAlD
Sunitinib—CHEK2—Paclitaxel—Docetaxel—prostate cancer	6.92e-05	0.0269	CbGdCrCtD
Sunitinib—YES1—testis—prostate cancer	6.91e-05	0.000755	CbGeAlD
Sunitinib—STK10—testis—prostate cancer	6.85e-05	0.000748	CbGeAlD
Sunitinib—PRKAA1—lymph node—prostate cancer	6.84e-05	0.000747	CbGeAlD
Sunitinib—TAOK3—testis—prostate cancer	6.82e-05	0.000745	CbGeAlD
Sunitinib—PDGFRA—testis—prostate cancer	6.78e-05	0.000741	CbGeAlD
Sunitinib—PTK2B—lymph node—prostate cancer	6.76e-05	0.000739	CbGeAlD
Sunitinib—ABCG2—prostate gland—prostate cancer	6.75e-05	0.000738	CbGeAlD
Sunitinib—FLT4—lymph node—prostate cancer	6.74e-05	0.000737	CbGeAlD
Sunitinib—CSNK1E—lymph node—prostate cancer	6.65e-05	0.000727	CbGeAlD
Sunitinib—FGFR1—lymph node—prostate cancer	6.65e-05	0.000727	CbGeAlD
Sunitinib—IRAK4—lymph node—prostate cancer	6.55e-05	0.000716	CbGeAlD
Sunitinib—ABCC4—renal system—prostate cancer	6.52e-05	0.000712	CbGeAlD
Sunitinib—KCNH2—seminal vesicle—prostate cancer	6.42e-05	0.000701	CbGeAlD
Sunitinib—ULK3—lymph node—prostate cancer	6.4e-05	0.0007	CbGeAlD
Sunitinib—MAP2K2—lymph node—prostate cancer	6.4e-05	0.0007	CbGeAlD
Sunitinib—MAP3K2—lymph node—prostate cancer	6.36e-05	0.000695	CbGeAlD
Sunitinib—KIT—bone marrow—prostate cancer	6.34e-05	0.000693	CbGeAlD
Sunitinib—ABCC2—renal system—prostate cancer	6.31e-05	0.00069	CbGeAlD
Sunitinib—MAP3K7—lymph node—prostate cancer	6.3e-05	0.000688	CbGeAlD
Sunitinib—CYP3A5—prostate gland—prostate cancer	6.27e-05	0.000685	CbGeAlD
Sunitinib—FGFR2—Estradiol—Ethinyl Estradiol—prostate cancer	6.24e-05	0.0242	CbGdCrCtD
Sunitinib—TBK1—lymph node—prostate cancer	6.23e-05	0.00068	CbGeAlD
Sunitinib—PDGFRB—bone marrow—prostate cancer	6.19e-05	0.000676	CbGeAlD
Sunitinib—TYK2—lymph node—prostate cancer	6.18e-05	0.000676	CbGeAlD
Sunitinib—KDR—testis—prostate cancer	6.11e-05	0.000668	CbGeAlD
Sunitinib—MAP2K5—testis—prostate cancer	6.11e-05	0.000668	CbGeAlD
Sunitinib—IRAK1—lymph node—prostate cancer	6.1e-05	0.000667	CbGeAlD
Sunitinib—RPS6KB1—lymph node—prostate cancer	5.99e-05	0.000654	CbGeAlD
Sunitinib—CSF1R—testis—prostate cancer	5.97e-05	0.000652	CbGeAlD
Sunitinib—FGR—lymph node—prostate cancer	5.95e-05	0.00065	CbGeAlD
Sunitinib—RET—lymph node—prostate cancer	5.95e-05	0.00065	CbGeAlD
Sunitinib—AXL—lymph node—prostate cancer	5.93e-05	0.000648	CbGeAlD
Sunitinib—PLK4—Fulvestrant—Estradiol—prostate cancer	5.73e-05	0.0222	CbGdCrCtD
Sunitinib—ABCG2—seminal vesicle—prostate cancer	5.71e-05	0.000624	CbGeAlD
Sunitinib—SLK—lymph node—prostate cancer	5.71e-05	0.000624	CbGeAlD
Sunitinib—JAK2—lymph node—prostate cancer	5.63e-05	0.000615	CbGeAlD
Sunitinib—FYN—lymph node—prostate cancer	5.55e-05	0.000606	CbGeAlD
Sunitinib—MAP3K3—lymph node—prostate cancer	5.42e-05	0.000593	CbGeAlD
Sunitinib—MAP4K5—lymph node—prostate cancer	5.42e-05	0.000593	CbGeAlD
Sunitinib—KIT—testis—prostate cancer	5.42e-05	0.000592	CbGeAlD
Sunitinib—CHEK2—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	5.3e-05	0.0206	CbGdCrCtD
Sunitinib—PDGFRB—testis—prostate cancer	5.29e-05	0.000578	CbGeAlD
Sunitinib—FLT1—lymph node—prostate cancer	5.24e-05	0.000573	CbGeAlD
Sunitinib—EPHB6—lymph node—prostate cancer	5.18e-05	0.000566	CbGeAlD
Sunitinib—KCNH2—renal system—prostate cancer	5.17e-05	0.000565	CbGeAlD
Sunitinib—KCNH2—urethra—prostate cancer	5.08e-05	0.000555	CbGeAlD
Sunitinib—CHEK2—Fulvestrant—Estradiol—prostate cancer	5.05e-05	0.0196	CbGdCrCtD
Sunitinib—PLK4—Teniposide—Etoposide—prostate cancer	5.04e-05	0.0196	CbGdCrCtD
Sunitinib—YES1—lymph node—prostate cancer	5.01e-05	0.000547	CbGeAlD
Sunitinib—STK10—lymph node—prostate cancer	4.96e-05	0.000542	CbGeAlD
Sunitinib—TAOK3—lymph node—prostate cancer	4.94e-05	0.00054	CbGeAlD
Sunitinib—ABCC4—bone marrow—prostate cancer	4.93e-05	0.000539	CbGeAlD
Sunitinib—PDGFRA—lymph node—prostate cancer	4.91e-05	0.000537	CbGeAlD
Sunitinib—ABCG2—urethra—prostate cancer	4.52e-05	0.000494	CbGeAlD
Sunitinib—CHEK2—Podofilox—Etoposide—prostate cancer	4.44e-05	0.0173	CbGdCrCtD
Sunitinib—CHEK2—Teniposide—Etoposide—prostate cancer	4.44e-05	0.0173	CbGdCrCtD
Sunitinib—KDR—lymph node—prostate cancer	4.43e-05	0.000484	CbGeAlD
Sunitinib—MAP2K5—lymph node—prostate cancer	4.43e-05	0.000484	CbGeAlD
Sunitinib—CSF1R—lymph node—prostate cancer	4.33e-05	0.000473	CbGeAlD
Sunitinib—CSNK1E—Danazol—Ethinyl Estradiol—prostate cancer	4.3e-05	0.0167	CbGdCrCtD
Sunitinib—CYP3A5—renal system—prostate cancer	4.27e-05	0.000467	CbGeAlD
Sunitinib—ABCC4—testis—prostate cancer	4.21e-05	0.00046	CbGeAlD
Sunitinib—ABCC2—testis—prostate cancer	4.08e-05	0.000446	CbGeAlD
Sunitinib—KIT—lymph node—prostate cancer	3.93e-05	0.000429	CbGeAlD
Sunitinib—KCNH2—bone marrow—prostate cancer	3.91e-05	0.000427	CbGeAlD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—prostate cancer	3.85e-05	0.015	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—prostate cancer	3.85e-05	0.015	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—prostate cancer	3.85e-05	0.015	CbGdCrCtD
Sunitinib—PDGFRB—lymph node—prostate cancer	3.84e-05	0.000419	CbGeAlD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—prostate cancer	3.56e-05	0.0138	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—prostate cancer	3.56e-05	0.0138	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—prostate cancer	3.56e-05	0.0138	CbGdCrCtD
Sunitinib—ABCG2—bone marrow—prostate cancer	3.48e-05	0.00038	CbGeAlD
Sunitinib—KCNH2—testis—prostate cancer	3.34e-05	0.000365	CbGeAlD
Sunitinib—ABCB1—prostate gland—prostate cancer	3.33e-05	0.000364	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Epirubicin—prostate cancer	3.32e-05	0.0129	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—prostate cancer	3.32e-05	0.0129	CbGdCrCtD
Sunitinib—CYP3A4—renal system—prostate cancer	3.21e-05	0.00035	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—prostate cancer	3.07e-05	0.0119	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—prostate cancer	3.07e-05	0.0119	CbGdCrCtD
Sunitinib—ABCC4—lymph node—prostate cancer	3.05e-05	0.000334	CbGeAlD
Sunitinib—ABCG2—testis—prostate cancer	2.97e-05	0.000325	CbGeAlD
Sunitinib—ABCC2—lymph node—prostate cancer	2.96e-05	0.000323	CbGeAlD
Sunitinib—PRPF4—Norethindrone—Ethinyl Estradiol—prostate cancer	2.85e-05	0.0111	CbGdCrCtD
Sunitinib—ABCB1—seminal vesicle—prostate cancer	2.82e-05	0.000308	CbGeAlD
Sunitinib—PLK4—Idarubicin—Epirubicin—prostate cancer	2.63e-05	0.0102	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—prostate cancer	2.63e-05	0.0102	CbGdCrCtD
Sunitinib—ABCB1—epithelium—prostate cancer	2.45e-05	0.000267	CbGeAlD
Sunitinib—PLK4—Idarubicin—Doxorubicin—prostate cancer	2.43e-05	0.00945	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—prostate cancer	2.43e-05	0.00945	CbGdCrCtD
Sunitinib—KCNH2—lymph node—prostate cancer	2.42e-05	0.000265	CbGeAlD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—prostate cancer	2.32e-05	0.009	CbGdCrCtD
Sunitinib—ABCB1—renal system—prostate cancer	2.27e-05	0.000248	CbGeAlD
Sunitinib—PRPF4—Levonorgestrel—Ethinyl Estradiol—prostate cancer	2.26e-05	0.0088	CbGdCrCtD
Sunitinib—ABCB1—urethra—prostate cancer	2.23e-05	0.000244	CbGeAlD
Sunitinib—CHEK2—Danazol—Ethinyl Estradiol—prostate cancer	2.2e-05	0.00856	CbGdCrCtD
Sunitinib—ABCG2—lymph node—prostate cancer	2.16e-05	0.000236	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—prostate cancer	2.14e-05	0.00833	CbGdCrCtD
Sunitinib—CHEK2—Norethindrone—Ethinyl Estradiol—prostate cancer	1.98e-05	0.00771	CbGdCrCtD
Sunitinib—Rash—Estradiol—prostate cancer	1.78e-05	0.000137	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—prostate cancer	1.78e-05	0.000137	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—prostate cancer	1.78e-05	0.000137	CcSEcCtD
Sunitinib—Dermatitis—Estradiol—prostate cancer	1.78e-05	0.000137	CcSEcCtD
Sunitinib—Anaemia—Prednisone—prostate cancer	1.77e-05	0.000137	CcSEcCtD
Sunitinib—Headache—Estradiol—prostate cancer	1.77e-05	0.000137	CcSEcCtD
Sunitinib—Skin disorder—Docetaxel—prostate cancer	1.76e-05	0.000136	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	1.76e-05	0.000136	CcSEcCtD
Sunitinib—Oedema—Capecitabine—prostate cancer	1.76e-05	0.000136	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—prostate cancer	1.76e-05	0.000136	CcSEcCtD
Sunitinib—Angioedema—Prednisone—prostate cancer	1.75e-05	0.000136	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—prostate cancer	1.75e-05	0.000135	CcSEcCtD
Sunitinib—Infection—Capecitabine—prostate cancer	1.75e-05	0.000135	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—prostate cancer	1.74e-05	0.000135	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—prostate cancer	1.73e-05	0.000134	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—prostate cancer	1.73e-05	0.000134	CcSEcCtD
Sunitinib—Anorexia—Docetaxel—prostate cancer	1.73e-05	0.000134	CcSEcCtD
Sunitinib—Shock—Capecitabine—prostate cancer	1.73e-05	0.000134	CcSEcCtD
Sunitinib—Body temperature increased—Etoposide—prostate cancer	1.73e-05	0.000134	CcSEcCtD
Sunitinib—Abdominal pain—Etoposide—prostate cancer	1.73e-05	0.000134	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—prostate cancer	1.73e-05	0.000134	CcSEcCtD
Sunitinib—Nervous system disorder—Capecitabine—prostate cancer	1.72e-05	0.000133	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—prostate cancer	1.72e-05	0.000133	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—prostate cancer	1.72e-05	0.000133	CcSEcCtD
Sunitinib—Thrombocytopenia—Capecitabine—prostate cancer	1.72e-05	0.000133	CcSEcCtD
Sunitinib—ABCB1—bone marrow—prostate cancer	1.72e-05	0.000187	CbGeAlD
Sunitinib—Hypoaesthesia—Epirubicin—prostate cancer	1.72e-05	0.000133	CcSEcCtD
Sunitinib—Skin disorder—Capecitabine—prostate cancer	1.71e-05	0.000132	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—prostate cancer	1.7e-05	0.000132	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—prostate cancer	1.7e-05	0.000131	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—prostate cancer	1.69e-05	0.000131	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—prostate cancer	1.69e-05	0.000131	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—prostate cancer	1.68e-05	0.00013	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—prostate cancer	1.68e-05	0.00013	CcSEcCtD
Sunitinib—Anorexia—Capecitabine—prostate cancer	1.68e-05	0.00013	CcSEcCtD
Sunitinib—Nausea—Estradiol—prostate cancer	1.67e-05	0.00013	CcSEcCtD
Sunitinib—Vomiting—Mitoxantrone—prostate cancer	1.67e-05	0.000129	CcSEcCtD
Sunitinib—Convulsion—Prednisone—prostate cancer	1.66e-05	0.000129	CcSEcCtD
Sunitinib—Hypertension—Prednisone—prostate cancer	1.66e-05	0.000128	CcSEcCtD
Sunitinib—Rash—Mitoxantrone—prostate cancer	1.66e-05	0.000128	CcSEcCtD
Sunitinib—Dermatitis—Mitoxantrone—prostate cancer	1.66e-05	0.000128	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Docetaxel—prostate cancer	1.65e-05	0.000128	CcSEcCtD
Sunitinib—Headache—Mitoxantrone—prostate cancer	1.65e-05	0.000127	CcSEcCtD
Sunitinib—Insomnia—Docetaxel—prostate cancer	1.64e-05	0.000127	CcSEcCtD
Sunitinib—Arthralgia—Prednisone—prostate cancer	1.63e-05	0.000126	CcSEcCtD
Sunitinib—Myalgia—Prednisone—prostate cancer	1.63e-05	0.000126	CcSEcCtD
Sunitinib—Paraesthesia—Docetaxel—prostate cancer	1.63e-05	0.000126	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—prostate cancer	1.63e-05	0.000126	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—prostate cancer	1.62e-05	0.000126	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	1.62e-05	0.000125	CcSEcCtD
Sunitinib—Dyspnoea—Docetaxel—prostate cancer	1.62e-05	0.000125	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—prostate cancer	1.61e-05	0.000125	CcSEcCtD
Sunitinib—Hypersensitivity—Etoposide—prostate cancer	1.61e-05	0.000125	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—prostate cancer	1.6e-05	0.000124	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.6e-05	0.000124	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—prostate cancer	1.6e-05	0.000124	CcSEcCtD
Sunitinib—Flushing—Epirubicin—prostate cancer	1.6e-05	0.000124	CcSEcCtD
Sunitinib—Dyspepsia—Docetaxel—prostate cancer	1.6e-05	0.000124	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—prostate cancer	1.6e-05	0.000123	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—prostate cancer	1.6e-05	0.000123	CcSEcCtD
Sunitinib—Insomnia—Capecitabine—prostate cancer	1.59e-05	0.000123	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—prostate cancer	1.59e-05	0.000123	CcSEcCtD
Sunitinib—CHEK2—Levonorgestrel—Ethinyl Estradiol—prostate cancer	1.58e-05	0.00614	CbGdCrCtD
Sunitinib—Paraesthesia—Capecitabine—prostate cancer	1.58e-05	0.000122	CcSEcCtD
Sunitinib—Decreased appetite—Docetaxel—prostate cancer	1.58e-05	0.000122	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—prostate cancer	1.58e-05	0.000122	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—prostate cancer	1.57e-05	0.000122	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Docetaxel—prostate cancer	1.57e-05	0.000121	CcSEcCtD
Sunitinib—Asthenia—Etoposide—prostate cancer	1.57e-05	0.000121	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—prostate cancer	1.57e-05	0.000121	CcSEcCtD
Sunitinib—Dyspnoea—Capecitabine—prostate cancer	1.57e-05	0.000121	CcSEcCtD
Sunitinib—Oedema—Prednisone—prostate cancer	1.57e-05	0.000121	CcSEcCtD
Sunitinib—Fatigue—Docetaxel—prostate cancer	1.57e-05	0.000121	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—prostate cancer	1.56e-05	0.000121	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—prostate cancer	1.56e-05	0.000121	CcSEcCtD
Sunitinib—Nausea—Mitoxantrone—prostate cancer	1.56e-05	0.000121	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—prostate cancer	1.56e-05	0.00012	CcSEcCtD
Sunitinib—Infection—Prednisone—prostate cancer	1.56e-05	0.00012	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—prostate cancer	1.55e-05	0.00012	CcSEcCtD
Sunitinib—Constipation—Docetaxel—prostate cancer	1.55e-05	0.00012	CcSEcCtD
Sunitinib—Pain—Docetaxel—prostate cancer	1.55e-05	0.00012	CcSEcCtD
Sunitinib—Dyspepsia—Capecitabine—prostate cancer	1.55e-05	0.00012	CcSEcCtD
Sunitinib—Chills—Epirubicin—prostate cancer	1.55e-05	0.00012	CcSEcCtD
Sunitinib—Pruritus—Etoposide—prostate cancer	1.55e-05	0.00012	CcSEcCtD
Sunitinib—Shock—Prednisone—prostate cancer	1.54e-05	0.000119	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—prostate cancer	1.54e-05	0.000119	CcSEcCtD
Sunitinib—Nervous system disorder—Prednisone—prostate cancer	1.54e-05	0.000119	CcSEcCtD
Sunitinib—Decreased appetite—Capecitabine—prostate cancer	1.53e-05	0.000118	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—prostate cancer	1.52e-05	0.000118	CcSEcCtD
Sunitinib—Skin disorder—Prednisone—prostate cancer	1.52e-05	0.000118	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Capecitabine—prostate cancer	1.52e-05	0.000117	CcSEcCtD
Sunitinib—Fatigue—Capecitabine—prostate cancer	1.52e-05	0.000117	CcSEcCtD
Sunitinib—CSNK1E—Danazol—Prednisone—prostate cancer	1.51e-05	0.00587	CbGdCrCtD
Sunitinib—Mental disorder—Epirubicin—prostate cancer	1.51e-05	0.000117	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—prostate cancer	1.51e-05	0.000117	CcSEcCtD
Sunitinib—Pain—Capecitabine—prostate cancer	1.5e-05	0.000116	CcSEcCtD
Sunitinib—Constipation—Capecitabine—prostate cancer	1.5e-05	0.000116	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—prostate cancer	1.5e-05	0.000116	CcSEcCtD
Sunitinib—Erythema—Epirubicin—prostate cancer	1.5e-05	0.000116	CcSEcCtD
Sunitinib—Diarrhoea—Etoposide—prostate cancer	1.5e-05	0.000116	CcSEcCtD
Sunitinib—Anorexia—Prednisone—prostate cancer	1.49e-05	0.000115	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—prostate cancer	1.49e-05	0.000115	CcSEcCtD
Sunitinib—Gastrointestinal pain—Docetaxel—prostate cancer	1.49e-05	0.000115	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—prostate cancer	1.48e-05	0.000114	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—prostate cancer	1.48e-05	0.000114	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—prostate cancer	1.48e-05	0.000114	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—prostate cancer	1.47e-05	0.000114	CcSEcCtD
Sunitinib—ABCB1—testis—prostate cancer	1.47e-05	0.00016	CbGeAlD
Sunitinib—Back pain—Epirubicin—prostate cancer	1.45e-05	0.000112	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—prostate cancer	1.45e-05	0.000112	CcSEcCtD
Sunitinib—Dizziness—Etoposide—prostate cancer	1.45e-05	0.000112	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—prostate cancer	1.44e-05	0.000112	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—prostate cancer	1.44e-05	0.000111	CcSEcCtD
Sunitinib—Gastrointestinal pain—Capecitabine—prostate cancer	1.44e-05	0.000111	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—prostate cancer	1.44e-05	0.000111	CcSEcCtD
Sunitinib—Abdominal pain—Docetaxel—prostate cancer	1.44e-05	0.000111	CcSEcCtD
Sunitinib—Body temperature increased—Docetaxel—prostate cancer	1.44e-05	0.000111	CcSEcCtD
Sunitinib—Chills—Doxorubicin—prostate cancer	1.43e-05	0.000111	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Prednisone—prostate cancer	1.43e-05	0.00011	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—prostate cancer	1.43e-05	0.00011	CcSEcCtD
Sunitinib—Insomnia—Prednisone—prostate cancer	1.42e-05	0.00011	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—prostate cancer	1.41e-05	0.000109	CcSEcCtD
Sunitinib—Paraesthesia—Prednisone—prostate cancer	1.41e-05	0.000109	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—prostate cancer	1.4e-05	0.000108	CcSEcCtD
Sunitinib—Abdominal pain—Capecitabine—prostate cancer	1.39e-05	0.000107	CcSEcCtD
Sunitinib—Body temperature increased—Capecitabine—prostate cancer	1.39e-05	0.000107	CcSEcCtD
Sunitinib—Vomiting—Etoposide—prostate cancer	1.39e-05	0.000107	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—prostate cancer	1.39e-05	0.000107	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—prostate cancer	1.39e-05	0.000107	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—prostate cancer	1.39e-05	0.000107	CcSEcCtD
Sunitinib—Dyspepsia—Prednisone—prostate cancer	1.38e-05	0.000107	CcSEcCtD
Sunitinib—Rash—Etoposide—prostate cancer	1.38e-05	0.000107	CcSEcCtD
Sunitinib—Dermatitis—Etoposide—prostate cancer	1.38e-05	0.000106	CcSEcCtD
Sunitinib—Headache—Etoposide—prostate cancer	1.37e-05	0.000106	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—prostate cancer	1.37e-05	0.000106	CcSEcCtD
Sunitinib—Decreased appetite—Prednisone—prostate cancer	1.36e-05	0.000105	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—prostate cancer	1.36e-05	0.000105	CcSEcCtD
Sunitinib—Fatigue—Prednisone—prostate cancer	1.35e-05	0.000104	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—prostate cancer	1.34e-05	0.000104	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—prostate cancer	1.34e-05	0.000104	CcSEcCtD
Sunitinib—Constipation—Prednisone—prostate cancer	1.34e-05	0.000104	CcSEcCtD
Sunitinib—Hypersensitivity—Docetaxel—prostate cancer	1.34e-05	0.000103	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—prostate cancer	1.34e-05	0.000103	CcSEcCtD
Sunitinib—Cough—Epirubicin—prostate cancer	1.31e-05	0.000101	CcSEcCtD
Sunitinib—Asthenia—Docetaxel—prostate cancer	1.3e-05	0.000101	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—prostate cancer	1.3e-05	0.000101	CcSEcCtD
Sunitinib—Nausea—Etoposide—prostate cancer	1.3e-05	0.0001	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—prostate cancer	1.3e-05	0.0001	CcSEcCtD
Sunitinib—Hypersensitivity—Capecitabine—prostate cancer	1.3e-05	0.0001	CcSEcCtD
Sunitinib—Pruritus—Docetaxel—prostate cancer	1.29e-05	9.94e-05	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—prostate cancer	1.28e-05	9.93e-05	CcSEcCtD
Sunitinib—Gastrointestinal pain—Prednisone—prostate cancer	1.28e-05	9.9e-05	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—prostate cancer	1.28e-05	9.88e-05	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—prostate cancer	1.28e-05	9.88e-05	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—prostate cancer	1.28e-05	9.88e-05	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.27e-05	9.81e-05	CcSEcCtD
Sunitinib—Asthenia—Capecitabine—prostate cancer	1.26e-05	9.76e-05	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—prostate cancer	1.25e-05	9.66e-05	CcSEcCtD
Sunitinib—Pruritus—Capecitabine—prostate cancer	1.24e-05	9.62e-05	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—prostate cancer	1.24e-05	9.61e-05	CcSEcCtD
Sunitinib—Diarrhoea—Docetaxel—prostate cancer	1.24e-05	9.61e-05	CcSEcCtD
Sunitinib—Body temperature increased—Prednisone—prostate cancer	1.24e-05	9.57e-05	CcSEcCtD
Sunitinib—Abdominal pain—Prednisone—prostate cancer	1.24e-05	9.57e-05	CcSEcCtD
Sunitinib—Oedema—Epirubicin—prostate cancer	1.23e-05	9.47e-05	CcSEcCtD
Sunitinib—Infection—Epirubicin—prostate cancer	1.22e-05	9.41e-05	CcSEcCtD
Sunitinib—Cough—Doxorubicin—prostate cancer	1.21e-05	9.37e-05	CcSEcCtD
Sunitinib—Shock—Epirubicin—prostate cancer	1.21e-05	9.32e-05	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—prostate cancer	1.2e-05	9.31e-05	CcSEcCtD
Sunitinib—Diarrhoea—Capecitabine—prostate cancer	1.2e-05	9.3e-05	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—prostate cancer	1.2e-05	9.29e-05	CcSEcCtD
Sunitinib—Dizziness—Docetaxel—prostate cancer	1.2e-05	9.29e-05	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—prostate cancer	1.2e-05	9.27e-05	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—prostate cancer	1.2e-05	9.27e-05	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—prostate cancer	1.19e-05	9.2e-05	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—prostate cancer	1.18e-05	9.14e-05	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—prostate cancer	1.18e-05	9.14e-05	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—prostate cancer	1.18e-05	9.14e-05	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.17e-05	9.08e-05	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—prostate cancer	1.17e-05	9.03e-05	CcSEcCtD
Sunitinib—Dizziness—Capecitabine—prostate cancer	1.16e-05	8.99e-05	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—prostate cancer	1.16e-05	8.94e-05	CcSEcCtD
Sunitinib—Vomiting—Docetaxel—prostate cancer	1.15e-05	8.93e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Prednisone—prostate cancer	1.15e-05	8.92e-05	CcSEcCtD
Sunitinib—Rash—Docetaxel—prostate cancer	1.15e-05	8.86e-05	CcSEcCtD
Sunitinib—Dermatitis—Docetaxel—prostate cancer	1.14e-05	8.85e-05	CcSEcCtD
Sunitinib—Headache—Docetaxel—prostate cancer	1.14e-05	8.8e-05	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—prostate cancer	1.13e-05	8.77e-05	CcSEcCtD
Sunitinib—Infection—Doxorubicin—prostate cancer	1.13e-05	8.71e-05	CcSEcCtD
Sunitinib—Asthenia—Prednisone—prostate cancer	1.12e-05	8.69e-05	CcSEcCtD
Sunitinib—Vomiting—Capecitabine—prostate cancer	1.12e-05	8.65e-05	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.12e-05	8.63e-05	CcSEcCtD
Sunitinib—Shock—Doxorubicin—prostate cancer	1.12e-05	8.62e-05	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—prostate cancer	1.11e-05	8.6e-05	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—prostate cancer	1.11e-05	8.58e-05	CcSEcCtD
Sunitinib—Rash—Capecitabine—prostate cancer	1.11e-05	8.57e-05	CcSEcCtD
Sunitinib—Pruritus—Prednisone—prostate cancer	1.11e-05	8.57e-05	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—prostate cancer	1.11e-05	8.57e-05	CcSEcCtD
Sunitinib—Dermatitis—Capecitabine—prostate cancer	1.11e-05	8.57e-05	CcSEcCtD
Sunitinib—Headache—Capecitabine—prostate cancer	1.1e-05	8.52e-05	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—prostate cancer	1.1e-05	8.51e-05	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—prostate cancer	1.1e-05	8.51e-05	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—prostate cancer	1.09e-05	8.45e-05	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—prostate cancer	1.08e-05	8.35e-05	CcSEcCtD
Sunitinib—Nausea—Docetaxel—prostate cancer	1.08e-05	8.34e-05	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—prostate cancer	1.08e-05	8.34e-05	CcSEcCtD
Sunitinib—Diarrhoea—Prednisone—prostate cancer	1.07e-05	8.29e-05	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—prostate cancer	1.06e-05	8.23e-05	CcSEcCtD
Sunitinib—ABCB1—lymph node—prostate cancer	1.06e-05	0.000116	CbGeAlD
Sunitinib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.06e-05	8.18e-05	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—prostate cancer	1.06e-05	8.17e-05	CcSEcCtD
Sunitinib—Pain—Epirubicin—prostate cancer	1.05e-05	8.1e-05	CcSEcCtD
Sunitinib—Constipation—Epirubicin—prostate cancer	1.05e-05	8.1e-05	CcSEcCtD
Sunitinib—Nausea—Capecitabine—prostate cancer	1.04e-05	8.08e-05	CcSEcCtD
Sunitinib—Dizziness—Prednisone—prostate cancer	1.04e-05	8.01e-05	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.03e-05	7.99e-05	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—prostate cancer	1.03e-05	7.93e-05	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—prostate cancer	1.02e-05	7.87e-05	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—prostate cancer	1.01e-05	7.81e-05	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—prostate cancer	1e-05	7.75e-05	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—prostate cancer	9.98e-06	7.72e-05	CcSEcCtD
Sunitinib—Vomiting—Prednisone—prostate cancer	9.96e-06	7.7e-05	CcSEcCtD
Sunitinib—Rash—Prednisone—prostate cancer	9.88e-06	7.64e-05	CcSEcCtD
Sunitinib—Dermatitis—Prednisone—prostate cancer	9.87e-06	7.63e-05	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—prostate cancer	9.85e-06	7.62e-05	CcSEcCtD
Sunitinib—Headache—Prednisone—prostate cancer	9.81e-06	7.59e-05	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	9.79e-06	7.57e-05	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—prostate cancer	9.77e-06	7.56e-05	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—prostate cancer	9.69e-06	7.5e-05	CcSEcCtD
Sunitinib—Pain—Doxorubicin—prostate cancer	9.69e-06	7.5e-05	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—prostate cancer	9.68e-06	7.49e-05	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—prostate cancer	9.68e-06	7.49e-05	CcSEcCtD
Sunitinib—CSNK1E—Betamethasone—Prednisone—prostate cancer	9.65e-06	0.00375	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Prednisone—prostate cancer	9.65e-06	0.00375	CbGdCrCtD
Sunitinib—Nausea—Prednisone—prostate cancer	9.3e-06	7.19e-05	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—prostate cancer	9.27e-06	7.17e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—prostate cancer	9.03e-06	6.98e-05	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—prostate cancer	8.96e-06	6.93e-05	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—prostate cancer	8.96e-06	6.93e-05	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—prostate cancer	8.79e-06	6.8e-05	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—prostate cancer	8.67e-06	6.7e-05	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—prostate cancer	8.38e-06	6.48e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—prostate cancer	8.35e-06	6.46e-05	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—prostate cancer	8.13e-06	6.29e-05	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—prostate cancer	8.1e-06	6.26e-05	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—prostate cancer	8.02e-06	6.2e-05	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—prostate cancer	7.79e-06	6.02e-05	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—prostate cancer	7.76e-06	6e-05	CcSEcCtD
Sunitinib—CHEK2—Danazol—Prednisone—prostate cancer	7.74e-06	0.00301	CbGdCrCtD
Sunitinib—Rash—Epirubicin—prostate cancer	7.72e-06	5.97e-05	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—prostate cancer	7.72e-06	5.97e-05	CcSEcCtD
Sunitinib—Headache—Epirubicin—prostate cancer	7.67e-06	5.93e-05	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—prostate cancer	7.5e-06	5.8e-05	CcSEcCtD
Sunitinib—Nausea—Epirubicin—prostate cancer	7.28e-06	5.63e-05	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—prostate cancer	7.21e-06	5.57e-05	CcSEcCtD
Sunitinib—Rash—Doxorubicin—prostate cancer	7.15e-06	5.53e-05	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—prostate cancer	7.14e-06	5.52e-05	CcSEcCtD
Sunitinib—Headache—Doxorubicin—prostate cancer	7.1e-06	5.49e-05	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—prostate cancer	6.73e-06	5.21e-05	CcSEcCtD
Sunitinib—JAK2—Signaling Pathways—CDKN1B—prostate cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—prostate cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—prostate cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—prostate cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STAT3—prostate cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—prostate cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—prostate cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—prostate cancer	1.62e-07	1.1e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—prostate cancer	1.62e-07	1.1e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TGFB1—prostate cancer	1.62e-07	1.1e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—prostate cancer	1.62e-07	1.1e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CTNNB1—prostate cancer	1.62e-07	1.1e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTT1—prostate cancer	1.62e-07	1.1e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ACHE—prostate cancer	1.62e-07	1.1e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—prostate cancer	1.61e-07	1.1e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CTNNB1—prostate cancer	1.61e-07	1.1e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—prostate cancer	1.61e-07	1.1e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—prostate cancer	1.61e-07	1.1e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.6e-07	1.09e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EP300—prostate cancer	1.6e-07	1.09e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP3—prostate cancer	1.6e-07	1.09e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—prostate cancer	1.6e-07	1.09e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—prostate cancer	1.6e-07	1.09e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL2—prostate cancer	1.6e-07	1.09e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CYP1A1—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—prostate cancer	1.58e-07	1.08e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1A—prostate cancer	1.58e-07	1.08e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—prostate cancer	1.58e-07	1.08e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—prostate cancer	1.58e-07	1.08e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—prostate cancer	1.58e-07	1.07e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTEN—prostate cancer	1.58e-07	1.07e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—prostate cancer	1.58e-07	1.07e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ERCC2—prostate cancer	1.58e-07	1.07e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1A—prostate cancer	1.58e-07	1.07e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTEN—prostate cancer	1.57e-07	1.07e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—prostate cancer	1.57e-07	1.07e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EP300—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—INS—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—SRC—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PRKACB—prostate cancer	1.55e-07	1.05e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—prostate cancer	1.55e-07	1.05e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—prostate cancer	1.54e-07	1.05e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.53e-07	1.04e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—prostate cancer	1.53e-07	1.04e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CREBBP—prostate cancer	1.53e-07	1.04e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—prostate cancer	1.53e-07	1.04e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTEN—prostate cancer	1.52e-07	1.04e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—SRC—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—prostate cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—prostate cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—prostate cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—prostate cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—prostate cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTEN—prostate cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—prostate cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EP300—prostate cancer	1.51e-07	1.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1A—prostate cancer	1.51e-07	1.02e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—prostate cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—prostate cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTEN—prostate cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—prostate cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EP300—prostate cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—prostate cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—prostate cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—prostate cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—prostate cancer	1.48e-07	1.01e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—MTHFR—prostate cancer	1.48e-07	1.01e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—prostate cancer	1.48e-07	1.01e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—prostate cancer	1.48e-07	1.01e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—prostate cancer	1.48e-07	1e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—prostate cancer	1.48e-07	1e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—prostate cancer	1.47e-07	9.99e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—prostate cancer	1.47e-07	9.97e-07	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—prostate cancer	1.47e-07	9.97e-07	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—prostate cancer	1.47e-07	9.97e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—SRC—prostate cancer	1.47e-07	9.96e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—prostate cancer	1.47e-07	9.96e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—prostate cancer	1.46e-07	9.94e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NCOA2—prostate cancer	1.46e-07	9.94e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—prostate cancer	1.46e-07	9.93e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—SRC—prostate cancer	1.46e-07	9.91e-07	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—EP300—prostate cancer	1.45e-07	9.88e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARA—prostate cancer	1.45e-07	9.88e-07	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—prostate cancer	1.45e-07	9.87e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CD—prostate cancer	1.45e-07	9.86e-07	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—EP300—prostate cancer	1.44e-07	9.8e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—prostate cancer	1.44e-07	9.79e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EP300—prostate cancer	1.43e-07	9.74e-07	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—prostate cancer	1.43e-07	9.71e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—prostate cancer	1.43e-07	9.7e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—prostate cancer	1.42e-07	9.65e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—prostate cancer	1.41e-07	9.61e-07	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—prostate cancer	1.41e-07	9.58e-07	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—prostate cancer	1.41e-07	9.58e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—prostate cancer	1.41e-07	9.56e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—prostate cancer	1.4e-07	9.53e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—prostate cancer	1.4e-07	9.52e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—prostate cancer	1.4e-07	9.52e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—prostate cancer	1.4e-07	9.51e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—prostate cancer	1.4e-07	9.5e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—prostate cancer	1.4e-07	9.49e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.39e-07	9.48e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—prostate cancer	1.39e-07	9.47e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—SRC—prostate cancer	1.39e-07	9.47e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—prostate cancer	1.39e-07	9.47e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—prostate cancer	1.38e-07	9.4e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—prostate cancer	1.38e-07	9.39e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—NOS3—prostate cancer	1.37e-07	9.31e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CAV1—prostate cancer	1.37e-07	9.29e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—prostate cancer	1.37e-07	9.28e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.36e-07	9.26e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—prostate cancer	1.36e-07	9.26e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—prostate cancer	1.36e-07	9.24e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—prostate cancer	1.36e-07	9.22e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—prostate cancer	1.36e-07	9.22e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—prostate cancer	1.36e-07	9.22e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—prostate cancer	1.35e-07	9.2e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—prostate cancer	1.35e-07	9.17e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NQO1—prostate cancer	1.35e-07	9.16e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—prostate cancer	1.34e-07	9.14e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—prostate cancer	1.34e-07	9.13e-07	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—prostate cancer	1.34e-07	9.11e-07	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—prostate cancer	1.34e-07	9.1e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—prostate cancer	1.34e-07	9.08e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—prostate cancer	1.33e-07	9.06e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TH—prostate cancer	1.33e-07	9.03e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—prostate cancer	1.31e-07	8.93e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—prostate cancer	1.31e-07	8.92e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—prostate cancer	1.31e-07	8.92e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—prostate cancer	1.31e-07	8.91e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—prostate cancer	1.31e-07	8.88e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—prostate cancer	1.3e-07	8.86e-07	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—prostate cancer	1.3e-07	8.84e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—prostate cancer	1.29e-07	8.79e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.29e-07	8.78e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—prostate cancer	1.29e-07	8.77e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—prostate cancer	1.29e-07	8.75e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—prostate cancer	1.28e-07	8.73e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—prostate cancer	1.28e-07	8.73e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—prostate cancer	1.28e-07	8.69e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—prostate cancer	1.28e-07	8.67e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.26e-07	8.59e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—prostate cancer	1.26e-07	8.56e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—prostate cancer	1.25e-07	8.51e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GGT1—prostate cancer	1.25e-07	8.51e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—prostate cancer	1.25e-07	8.49e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—prostate cancer	1.25e-07	8.47e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—prostate cancer	1.25e-07	8.46e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CG—prostate cancer	1.24e-07	8.46e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—prostate cancer	1.24e-07	8.44e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—prostate cancer	1.24e-07	8.43e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—prostate cancer	1.24e-07	8.42e-07	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—prostate cancer	1.24e-07	8.4e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.23e-07	8.38e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—prostate cancer	1.22e-07	8.31e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—prostate cancer	1.22e-07	8.3e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.21e-07	8.26e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—prostate cancer	1.21e-07	8.25e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—prostate cancer	1.21e-07	8.21e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—prostate cancer	1.2e-07	8.16e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—prostate cancer	1.2e-07	8.16e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—prostate cancer	1.19e-07	8.06e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—INS—prostate cancer	1.18e-07	8.01e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—prostate cancer	1.18e-07	8e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—RXRA—prostate cancer	1.17e-07	7.97e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—prostate cancer	1.16e-07	7.86e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CREBBP—prostate cancer	1.15e-07	7.84e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—prostate cancer	1.15e-07	7.84e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—prostate cancer	1.15e-07	7.79e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—prostate cancer	1.14e-07	7.77e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—prostate cancer	1.14e-07	7.75e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—prostate cancer	1.14e-07	7.73e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—COMT—prostate cancer	1.13e-07	7.68e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—prostate cancer	1.13e-07	7.67e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.12e-07	7.64e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—prostate cancer	1.12e-07	7.61e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—prostate cancer	1.11e-07	7.58e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—prostate cancer	1.11e-07	7.54e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—prostate cancer	1.11e-07	7.53e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—prostate cancer	1.11e-07	7.53e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.11e-07	7.52e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CD—prostate cancer	1.09e-07	7.44e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTEN—prostate cancer	1.09e-07	7.42e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—prostate cancer	1.08e-07	7.33e-07	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—prostate cancer	1.08e-07	7.31e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—prostate cancer	1.07e-07	7.29e-07	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—prostate cancer	1.07e-07	7.25e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—prostate cancer	1.06e-07	7.2e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—prostate cancer	1.05e-07	7.15e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—prostate cancer	1.05e-07	7.13e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—prostate cancer	1.05e-07	7.13e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TYMS—prostate cancer	1.04e-07	7.1e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—EP300—prostate cancer	1.04e-07	7.08e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—NOS3—prostate cancer	1.03e-07	7.02e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTM1—prostate cancer	1.03e-07	7.02e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—prostate cancer	1.03e-07	6.97e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—prostate cancer	1.02e-07	6.96e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—LPL—prostate cancer	1.01e-07	6.89e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—prostate cancer	9.87e-08	6.71e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—prostate cancer	9.82e-08	6.68e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	9.79e-08	6.66e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ERCC2—prostate cancer	9.71e-08	6.6e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—prostate cancer	9.68e-08	6.58e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CB—prostate cancer	9.54e-08	6.48e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—prostate cancer	9.45e-08	6.42e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—prostate cancer	9.45e-08	6.42e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—prostate cancer	9.38e-08	6.38e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—MTHFR—prostate cancer	9.13e-08	6.2e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—prostate cancer	9.11e-08	6.19e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—prostate cancer	9.06e-08	6.16e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARA—prostate cancer	8.95e-08	6.09e-07	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—prostate cancer	8.78e-08	5.97e-07	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—prostate cancer	8.71e-08	5.92e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—prostate cancer	8.66e-08	5.89e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CAV1—prostate cancer	8.42e-08	5.72e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTEN—prostate cancer	8.24e-08	5.6e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—EP300—prostate cancer	7.86e-08	5.34e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—prostate cancer	7.7e-08	5.24e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	7.67e-08	5.21e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—INS—prostate cancer	7.26e-08	4.93e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CREBBP—prostate cancer	7.11e-08	4.83e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	6.74e-08	4.58e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NOS3—prostate cancer	6.36e-08	4.33e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—prostate cancer	6.29e-08	4.28e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	5.88e-08	3.99e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—prostate cancer	5.82e-08	3.96e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—prostate cancer	5.81e-08	3.95e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTEN—prostate cancer	5.08e-08	3.45e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—EP300—prostate cancer	4.84e-08	3.29e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—prostate cancer	4.75e-08	3.23e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.58e-08	2.44e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—prostate cancer	2.93e-08	1.99e-07	CbGpPWpGaD
